Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data may reveal which breast cancer subtype responds best to CDK4/6 inhibitors

NCT ID NCT07704801

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study looks back at medical records of 300 people with metastatic luminal A or luminal B breast cancer who were treated with CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib). The goal is to see how long patients lived without their cancer getting worse, and whether the subtype of their cancer affected how well the drugs worked. By comparing real-world outcomes, researchers hope to learn which patients benefit most from these targeted therapies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CDK4/6 inhibitors (Palbociclib, Ribociclib, or Abemaciclib)
What this could lead to
If successful, this study could help doctors choose the best CDK4/6 inhibitor for each breast cancer subtype, improving treatment personalization.
What could go wrong
This is a retrospective review of medical records, not a controlled trial, so results may be influenced by missing data or patient selection bias.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of female patients diagnosed with hormone receptor-positive, HER2-negative (Luminal A or Luminal B) metastatic breast cancer who were managed and treated with CDK4/6 inhibitors at Sohag University Hospital and SCI . Data will be extracted from their existing medical records.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients who are more than 18 years old at time of diagnosis and less than 80 years * metastatic breast cancer luminal A and luminal B of either sex Exclusion Criteria: * patients diagnosed with double malignancy * patients with incomplete medical records * patients with organ failure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm luminal A breast carcinoma luminal B breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic breast cancer

Contacts and locations

Locations

  • Sohag university hospital

    Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.